Skip to main content
SpringerLink
Log in

Improving DMT adherence in MS reduces relapse risk and costs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. The study was supported by AbbVie.

Reference

  • Burks J, et al. Adherence to disease-modifying therapies and its impact on relapse, health resource utilization, and costs among patients with multiple sclerosis. ClinicoEconomics and Outcomes Research : 28 Apr 2017. Available from: URL: https://doi.org/10.2147/CEOR.S130334

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Improving DMT adherence in MS reduces relapse risk and costs. PharmacoEcon Outcomes News 778, 21 (2017). https://doi.org/10.1007/s40274-017-3998-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-3998-4

Search

Navigation